**Relation between Neutrophil to lymphocyte ratio in diabetic patients and severity of ischemic heart disease**

Remon Saleh Adly Abdallah

Internal Medicine and Cardiology Department, Faculty of Medicine, Sohag University, Egypt.

remonsaleh@yahoo.com

**Abstract:** Type 2 diabetes (T2D) is a major global health problem that affects more than 285 million individuals worldwide. It alters components of the immune system and is associated with elevated levels of the inflammatory markers as interleukin 6 (IL6) and C-reactive protein (CRP) and in particular Neutrophil: lymphocyte ratio (NLR) which corresponds to numerous chronic inflammatory diseases. NLR is being related to arterial stiffness and high coronary calcium scores, which are significant markers of CVD. Inflammatory cells contribute to atherosclerotic lesion initiation and lesion disruption, which could cause acute coronary syndrome and other cardiovascular events. NLR is calculated as a simple ratio of the absolute neutrophil count to the absolute lymphocyte count. It was defined as a potential biomarker of inflammation in cardiovascular conditions, diabetes and its complications. Higher level of NLR is related to a higher severity of coronary artery disease and worsen clinical outcome in patients undergoing percutaneous coronary intervention (PCI).

[Remon Saleh Adly Abdallah. **Relation between Neutrophil to lymphocyte ratio in diabetic patients and severity of ischemic heart disease.** *N Y Sci J* 2019;12(9):24-27]. ISSN 1554-0200 (print); ISSN 2375-723X (online). <http://www.sciencepub.net/newyork>. 6. doi:[10.7537/marsnys120919.06](http://www.dx.doi.org/10.7537/marsnys120919.06).

**Keywords:** Relation; Neutrophil; lymphocyte; ratio; diabetic; ischemic heart disease

**Introduction**

Type 2 diabetes (T2D) is a major global health problem that affects more than 285 million individuals worldwide [(1),](http://www.eje-online.org/content/173/2/217.full#ref-1) and it has reached epidemic proportions in China. An estimated 92.4 million adults age 20 years or older (9.7% of the adult population) have diabetes, and 60.7% of these cases are undiagnosed [(2).](http://www.eje-online.org/content/173/2/217.full#ref-2) Another 148.2 million adults (15.5%) have pre-diabetes, which is an important risk factor for the development of overt diabetes as well as cardiovascular disease (CVD) ([3,](http://www.eje-online.org/content/173/2/217.full#ref-3) [4).](http://www.eje-online.org/content/173/2/217.full#ref-4) The increasing burden of T2D [(5) d](http://www.eje-online.org/content/173/2/217.full#ref-5)emonstrates an immediate need for elucidating the mechanisms that underlie its pathophysiology of in order to implement preventative strategies.

Prior studies have indicated that components of the immune system are altered in obesity and T2D [(6)](http://www.eje-online.org/content/173/2/217.full#ref-6) and that elevated levels of the inflammatory markers interleukin 6 (IL6) and C-reactive protein (CRP) are associated with the development of T2D [(7).](http://www.eje-online.org/content/173/2/217.full#ref-7) Other research has indicated that inflammation of pancreatic islets can reduce insulin secretion and trigger β-cell apoptosis [(8).](http://www.eje-online.org/content/173/2/217.full#ref-8) This led us to hypothesize that immune markers might be useful predictors of T2D.

**NLR as an inflammatory marker:**

Neutrophil: lymphocyte ratio (NLR), which has become one of the most popular biomarkers in biological and medical research in recent years, has been shown to correspond to numerous chronic inflammatory diseases ([9,](http://www.eje-online.org/content/173/2/217.full#ref-9) [10).](http://www.eje-online.org/content/173/2/217.full#ref-10) NLR is both accessible and affordable, and it thus has been increasingly used in clinical trials and research studies; however, few studies have examined the relationship between NLR and T2D [(11).](http://www.eje-online.org/content/173/2/217.full#ref-11)

NLR reflects both the lymphocyte and neutrophil counts. The power of NLR as an inflammatory factor stems from both a reduction in the lymphocyte count and an increase in the neutrophil count. Tanaka *et al*. [(12) s](http://www.eje-online.org/content/173/2/217.full#ref-30)howed that T lymphocytes were reduced in obese people and that lymphopenia appeared to be related to inflammation through TNFα. Neutrophils are the first immune cells to respond to inflammation and can exacerbate the chronic inflammatory state by helping recruit macrophages and by interacting with antigen-presenting cells. An animal study demonstrated that neutrophil elastase could degrade the insulin receptor substrate 1 and reduce insulin-induced Akt phosphorylation in adipocytes. This mechanism may be involved in the neutrophil effect on insulin resistance [(13)](http://www.eje-online.org/content/173/2/217.full#ref-31).

Several studies have established the utility of NLR as a medically relevant biomarker. NLR can single out individuals that are at risk for sensorineural hearing loss (caused by vascular complications of diabetes via inflammation) [(14) o](http://www.eje-online.org/content/173/2/217.full#ref-32)r those that are at risk for adverse cardiac events [(15).](http://www.eje-online.org/content/173/2/217.full#ref-33) One review article also indicated that NLR has been related to arterial stiffness and high coronary calcium scores, which are significant markers of CVD [(16).](http://www.eje-online.org/content/173/2/217.full#ref-34) Recently, NLR has been reported to be a prognostic marker for outcomes

that result from diabetic retinopathy [(17),](http://www.eje-online.org/content/173/2/217.full#ref-35) including microvascular complications [(18) a](http://www.eje-online.org/content/173/2/217.full#ref-36)nd impaired renal function [(19).](http://www.eje-online.org/content/173/2/217.full#ref-37) Although the precise mechanisms that underlie the associations between systemic inflammation and prevalent conditions remain to be elucidated, these studies verify the present conclusion that NLR could be used as an innovative and effective predictor for T2D.

**Inflammation and severity of atherosclerosis:**

Inflammation can be a cause of numerous diabetic complications that represent a complex set of phenomena that stretch beyond the field of inflammation proper. Corvera et al. [(20) p](http://www.eje-online.org/content/173/2/217.full#ref-38)roposed that during diabetic complications, the early formation of advanced glycation end products associated with hyperglycemia stimulates mechanisms that lead to the recruitment of key components of the inflammatory response. Indeed, studies have shown that the advanced glycation end products receptor-mediated regulation of adiposity and inflammation may result in T2D and diabetic vascular complications [(21).](http://www.eje-online.org/content/173/2/217.full#ref-39) Other research has shown that serum levels of IL6, IL17, interferon γ, TNFγ, IL2, and IL10 were increased in T2D nephropathy (T2DN) patients [(22),](http://www.eje-online.org/content/173/2/217.full#ref-40) and inflammatory responses (such as increased expression of toll-like receptors) were involved in the perpetuation of inflammation in the diabetic kidney [(23).](http://www.eje-online.org/content/173/2/217.full#ref-41) During the development and progression of T2DN, increased oxidative stress leads to the activation of the poly (ADP-ribose) polymerase pathway, which regulates the expression of genes that are involved in promoting inflammatory reactions [(24).](http://www.eje-online.org/content/173/2/217.full#ref-42) A study by Vinik *et al*. [(25) e](http://www.eje-online.org/content/173/2/217.full#ref-43)mphasized that a loss of heart rate variability, which occurs early in the development of autonomic dysfunction, correlates with an increase in circulating inflammation markers, such as CRP and IL6. Collectively and combined with the present findings, these results suggest that inflammation likely contributes to the pathophysiology of and complications that result from T2D.

Type 2 diabetes also increases the risk of atherosclerosis/cardiovascular disease two- to fivefold (26). Carotid artery intima-media thickness (cIMT), which serves as a well- established biomarker of subclinical atherosclerosis, is a risk factor for cardiovascular disease and can be used to predict cardiovascular events (27,28); it is significantly greater in patients with type 2 diabetes than that in non- diabetes subjects (29).

Some studies have pointed out that inflammation plays an important role in diabetes and its chronic complications, and is also associated with cardiovascular events (30-32). Inflammatory cells contribute to atherosclerotic lesion initiation and lesion disruption, which could cause acute coronary syndrome and other cardiovascular events. Several inflammatory markers (such as fibrinogen, C- reactive protein [CRP], interluekin-18 and tumor necrosis factor- a ), which are associated with markers of asymptomatic atherosclerosis in type 2 diabetes (33), are difficult to obtain in common clinical practice. Therefore, simpler and more convenient markers are required.

Mounting evidence has shown that the white blood cell (WBC) count and its subtypes are classic indicators of inflammation (34). The neutrophil-to- lymphocyte ratio (NLR) was calculated as a simple ratio of the absolute neutrophil count to the absolute lymphocyte count. It was defined as a potential biomarker of inflammation in tumors (35-37), cardiovascular conditions (38,39), and diabetes and its complications (40,41). Previous studies have shown that a higher level of NLR was related to a higher severity of coronary artery disease and worse clinical outcome in patients undergoing percutaneous coronary intervention (42-45). Akbasetal. (18) reported that the level of NLR was significantly higher in diabetic nephropathy patients with albuminuria. Uluetal. (46) also reported a positive correlation between the NLR and different diabetic retinopathy grades.

The exact mechanisms of the higher level of NLR being associated with diabetes and its complications are still unclear, and the most important mechanism might be inflammation. However, the relationship between diabetic cIMT and NLR has not been investigated to date. The objective of the present study was to investigate the role of NLR in cIMT development among type 2 diabetes patients.

**Conclusion:**

NLR is increased as inflammatory marker in diabetic patients and, in those patients, this is independently associated with advanced atherosclerosis and both the prevalence and severity of Coronary artery disease.

**Conflict of interest**: None

**Funding:** No

**References**

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010 87 4–14.
2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q et al. Prevalence of diabetes among men and women in China. New England Journal of Medicine 2010 362 1090–1101.
3. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR & Chambless LE. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005 28 2013–2018.
4. Levitzky YS, Pencina MJ, D'Agostino RB, Meigs JB, Murabito JM, Vasan RS & Fox CS. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. Journal of American College of Cardiology 2008 51 264–270.
5. Li R, Lu W, Jiang QW, Li YY, Zhao GM, Shi L, Yang QD, Ruan Y, Jiang J, Zhang SN et al. Increasing prevalence of type 2 diabetes in Chinese adults in Shanghai. Diabetes Care 2012 35 1028–1030.
6. Donath MY & Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Reviews. Immunology 2011 11 98–107.
7. Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001 286 327–334.
8. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Halban PA & Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends in Endocrinology and Metabolism 2010 21 261–267.
9. Avci A, Elnur A, Goksel A, Serdar F, Servet I, Atilla K, Mustafa TM, Cuneyt T, Yeliz G, Mustafa B et al. The relationship between neutrophil/lymphocyte ratio and calcific aortic stenosis. Echocardiography 2014 31 1031–1035.
10. Farah R & Khamisy-Farah R. Association of neutrophil to lymphocyte ratio with presence and severity of gastritis due to Helicobacter pylori infection. Journal of Clinical Laboratory Analysis 2014 28 219–223.
11. Lorenzo C, Hanley AJ & Haffner SM. Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 2014 57 83–92.
12. Tanaka S, Isoda F, Ishihara Y, Kimura M & Yamakawa T. T ymphopaenia in relation to body mass index and TNF-α in human obesity: adequate weight reduction can be corrective. Clinical Endocrinology 2001 54 347–354.
13. Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nature Medicine 2012 18 1407–1412.
14. Sukhija R, Aronow WS, Sorbera C, Peterson SJ, Frishman WH & Cohen M. Mortality, left ventricular ejection fraction, and prevalence of new left ventricular wall motion abnormality at long-term follow-up in patients with implantable cardioverter defibrillators treated with biventricular pacing versus right ventricular pacing. American Journal of Therapeutics 2007 14 328–330.
15. Azab B, Chainani V, Shah N & McGinn JT. Neutrophil–lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4- year follow-up study. Angiology 2013 64 456–465.
16. Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M & Costantino T. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Review of Cardiovascular Therapy 2013 11 55–59.
17. Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acarturk G & Inan S. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. Diabetes Technology & Therapeutics 2013 15 942–947.
18. Ozturk ZA, Kuyumcu ME, Yesil Y, Savas E, Yildiz H, Kepekci Y & Ariogul S. Is there a link between neutrophil–lymphocyte ratio and microvascular complications in geriatric diabetic patients? Journal of Endocrinological Investigation 2013 36 593–599.
19. Azab B, Daoud J, Naeem FB, Nasr R, Ross J, Ghimire P, Siddiqui A, Azzi N, Rihana N, Abdallah M et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Renal Failure 2012 34 571–576.
20. Corvera S, Burkart A, Kim JY, Christianson J, Wang Z & Scherer PE. Keystone meeting summary: ‘Adipogenesis, obesity, and inflammation’ and ‘Diabetes mellitus and the control of cellular energy metabolism,’ January 26, 2006, Vancouver, Canada. Genes Development 2006 20 2193–2201.
21. Yamamoto Y & Yamamoto H. RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication. Frontiers in Endocrinology 2013 4 105.
22. Zhang C, Xiao C, Wang P, Xu W, Zhang A, Li Q & Xu X. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Human Immunology 2014 75 289–296.
23. Mudaliar H, Pollock C & Panchapakesan U. Role of toll-like receptors in diabetic nephropathy. Clinical Science 2014 126 685–694.
24. Edwards JL, Vincent AM, Cheng HT & Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & Therapeutics 2008 120 1–34.
25. Vinik AI, Erbas T & Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. Journal of Diabetes Investigation 2013 4 4–18.
26. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728 –1735.
27. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotidintima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432 –1437.
28. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intimaand media thickness as a risk factor for myocardial infarction and stroke in older adults Cardiovascular Health Study Collaborative Research Group. NEngl JMed 1999; 340: 14 –22.
29. Taniwaki H, Kawagishi T, Emoto M, et al. Correlation between the intima- media thickness of the carotid artery and aortic pulse-wave velocity in patients with type diabetes. Vessel wall properties in type 2 diabetes. Diabetes Care 1999; 22: 1851 –1857.
30. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Commu nities study): a cohort study. Lancet 1999; 353: 1649 – 1652.
31. Fujita T, Hemmi S, Kajiwara M, et al. Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev 2013; 29: 220 –226.
32. Ross R. Atherosclerosis: an inflammatory disease. NEngl JMed1999; 340: 115–126.
33. Ray A, Huisman MV, Tamsma JT, et al. The role of inflammation on atherosclerosis, intermediate and clinical cardiovascular endpoints in type 2 diabetes mellitus. Eur J Intern Med 2009; 20: 253 – 260.
34. Horne BD, Anderson JL, John JM, et al. Which white bloodcell subtypes predict increased cardiovascular risk? JAm Coll Cardiol 2005; 45: 1638 –1643.
35. Gunduz S, Mutlu H, Tural D, et al. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol 2015; 11: 288 – 292.
36. Ozaksit G, Tokmak A, Kalkan H, et al. Value of the platelet to lymphocyte ratio in the diagnosis of ovarian neoplasms in adolescents. Asian Pac J Cancer Prev 2015; 16: 2037 – 2041.
37. Liu J, Du J, Fan J, et al. The neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma. ORL J Otorhinolaryngol Relat Spec 2015; 77: 109 – 116.
38. Akyel A, Yayla C ß, Erat M, et al. Neutrophil-to-lymphocyte ratio predicts hemodynamic significance of coronary artery stenosis. Anatol J Cardiol 2015; 15: 1002 – 1007.
39. Oylumlu M, Yildiz A, Oylumlu M, et al. Platelet-to- lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anatol J Cardiol 2015; 15: 277 – 283.
40. Akbas EM, Demirtas L, Ozcicek A, et al. Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic nephropathy. Int J Clin Exp Med 2014; 7: 1794 – 1801.
41. Shiny A, Bibin YS, Shanthirani CS, et al. Association of neutrophil- lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. Diabetes Technol Ther 2014; 16: 524 – 530.
42. Poludasu S, Cavusoglu E, Khan W, et al. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol 2009; 32: E6 – E10.
43. Shen XH, Chen Q, Shi Y, et al. Association of neutrophil/ lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl) 2010; 123:3438 – 3443.
44. Sen N, Afsar B, Ozcan F, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013; 228: 203 – 210.
45. Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013; 111: 636 – 642.
46. Ulu SM, Dogan M, Ahsen A, et al. Neutrophil-to lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. Diabetes Technol Ther 2013; 15: 942 – 947.

9/8/2019